Dec 17 2010
Medivir AB (STO:MVIRB)(OMX:MVIR), the emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that NASDAQ OMX Stockholm is promoting Medivir AB (MVIR B) from the Small Cap to the Mid Cap List. The change is effective as of January 3, 2011.
Ron Long, CEO of Medivir commented, "Medivir has had a very successful year with many important operational, as well as financial milestones achieved during the year. The Medivir share price has performed strongly during 2010 and our ambition of creating value for our shareholders will continue. The move to the Mid Cap List is an important step for the Company's future development."
The NASDAQ Mid Cap List is for companies with a market cap between 150 million euro and 1 billion euro.
SOURCE Medivir AB